Head to head
Viatris vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: VTRS · TAK
VTRS
Viatris
17.49-0.29%
1-year price shape — +78% over the period
Quant Rating B · 91/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
| VTRS | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 17.49 | 18.37 |
| Change today | -0.29% | +1.49% |
| 1-year return | +78.5% | +29.2% |
| Market cap | $20.09B | $58.68B |
| 52-week range | 9.40 – 18.43 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -47.27 | -55.67 |
| P/E percentile, own 5-yr range | 10th | 4th |
| P/B | 1.41 | 1.23 |
| Dividend yield | 2.74% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | -3.00 | -0.31 |
| Net profit (TTM) | $-3.45B | $-977.54M |
| Revenue (TTM) | $14.74B | $4.62T |
| Revenue growth (YoY) | +4.9% | +10.2% |
| Gross margin | 34.8% | 65.5% |
| Operating margin | 0.9% | 10.4% |
| Net margin | -2.8% | -3.5% |
| Free cash flow (TTM) | $1.81B | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 96.3% | 51.5% |
| Insider activity (12mo) | 40 buy / 10 sell | 22 buy / 28 sell |
| Short interest (% of float) | 3.6% | 0.1% |
| Analyst consensus | 62% buy / 25% hold / 12% sell (8) | 100% buy (1) |
| Analyst price target | $20 (+16%) | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | B (91) | C (70) |
| Company | ||
| Employees | 30,000 | 47,029 |
| Founded | 2019 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.